Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Platelet-rich plasma (PRP) is an autologous biologic therapy prepared by concentrating platelets from a patient's own peripheral blood. The Medical University of Lodz is investigating the use of the Tropocells® PRP system in a randomized clinical trial (NCT06631976) for patients with supraspinatus tendon injuries who experience significant sleep disturbances due to shoulder pain. PRP functions by releasing a high concentration of growth factors—such as platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF)—upon injection into the injured tendon. These factors stimulate tissue repair, collagen synthesis, and angiogenesis, aiming to accelerate healing, reduce pain, and consequently improve sleep quality and shoulder function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tropocells PRP.